



Vaccines against Pneumococcal Infection

Guest Editor:

Prof. Dr. Alan Cross

Center for Vaccine Development
and Global Health, Department
of Medicine, University of
Maryland School of Medicine,
Baltimore, MD 21201, USA

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editor

Streptococcus pneumoniae is a significant cause of community-acquired morbidity and mortality worldwide in both pediatric and adult populations. In addition to being an important cause of respiratory infections, including pneumonia and otitis media, it also is a leading cause of sepsis and meningitis. In addition to current glycoconjugate vaccines, novel formulations of pneumococcal vaccines are being developed that include non-CPS antigens and induction of Th17 immune responses that may enhance mucosal immunity. I would like to encourage submission to this special issue manuscripts that identify the distribution of pneumococcal capsular polysaccharide serotypes prevalent in various geographic locales and the impact of pneumococcal immunization. I also welcome articles that review the pathophysiology of pneumococcal infection, particularly those that identify novel targets and/or strategies for next-generation pneumococcal vaccines conferring broad coverage. Discussions of novel aspects of the immune responses to these vaccines are also desirable.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com